EGFR in melanoma: Clinical significance and potential therapeutic target

Journal of Cutaneous Pathology

Volumn 38, Issue 6, 2011, Pages 492-502

  Boone, Barbara ^a   Jacobs, Koen ^a   Ferdinande, Liesbeth ^a   Taildeman, Jasmien ^a   Lambert, Jo ^a   Peeters, Marc ^a   Bracke, Marc ^a   Pauwels, Patrick ^a   Brochez, Lieve ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

cancer research; dermatopathology; malignant melanoma

Indexed keywords

EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; ARTICLE; BIOSYNTHESIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MELANOMA; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SKIN TUMOR; WESTERN BLOTTING;

ADULT; BLOTTING, WESTERN; FEMALE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; SKIN NEOPLASMS;

EID: 79955532871     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2011.01673.x     Document Type: Article

References (33)

1. Riese DJ II, Stern DF., Specificity within the EGF family/ErbB receptor family signaling network. Bioessays 1998; 20: 41.
2. Miettinen PJ, Berger JE, Meneses J, et al., Epithelial immaturity and multiorgan failure in mice lacking epidermal growth factor receptor. Nature 1995; 376: 337.
3. Normanno N, De Luca A, Bianco C, et al., Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006; 366: 2.
4. Nicholson RI, Gee JM, Harper ME., EGFR and cancer prognosis. Eur J Cancer 2001; 37 (Suppl. 4): S9.
5. Sequist LV, Bell DW, Lynch TJ, Haber DA., Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 2007; 25: 587.
6. Rowinsky EK., The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. Annu Rev Med 2004; 55: 433.
7. Real FX, Rettig WJ, Chesa PG, Melamed MR, Old LJ, Mendelsohn J., Expression of epidermal growth factor receptor in human cultured cells and tissues: relationship to cell lineage and stage of differentiation. Cancer Res 1986; 46: 4726.
8. Elder DE, Rodeck U, Thurin J, et al., Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer Res 1989; 49: 5091.
9. de Wit PE, Moretti S, Koenders PG, et al., Increasing epidermal growth factor receptor expression in human melanocytic tumor progression. J Invest Dermatol 1992; 99: 168.
10. Sparrow LE, Heenan PJ., Differential expression of epidermal growth factor receptor in melanocytic tumors demonstrated by immunohistochemistry and mRNA in situ hybridization. Australas J Dermatol 1999; 40: 19.
11. Ellis DL, King LE Jr, Nanney LB., Increased epidermal growth factor receptors in melanocytic lesions. J Am Acad Dermatol 1992; 27: 539.
12. Akslen LA, Puntervoll H, Bachmann IM, et al., Mutation analysis of the EGFR-NRAS-BRAF pathway in melanomas from black Africans and other subgroups of cutaneous melanoma. Melanoma Res 2008; 18: 29.
13. Rakosy Z, Vizkeleti L, Ecsedi S, et al., EGFR gene copy number alterations in primary cutaneous malignant melanomas are associated with poor prognosis. Int J Cancer 2007; 121: 1729.
14. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D., Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res 1998; 58: 2170.
15. Trent JM, Meyskens FL, Salmon SE, et al., Relation of cytogenetic abnormalities and clinical outcome in metastatic melanoma. N Engl J Med 1990; 322: 1508.
16. Udart M, Utikal J, Krahn GM, Peter RU., Chromosome 7 aneusomy. A marker for metastatic melanoma? Expression of the epidermal growth factor receptor gene and chromosome 7 aneusomy in nevi, primary malignant melanomas and metastases. Neoplasia 2001; 3: 245.
17. Mueller BM, Romerdahl CA, Trent JM, Reisfeld RA., Suppression of spontaneous melanoma metastasis in SCID mice with an antibody to the epidermal growth factor receptor. Cancer Res 1991; 51: 2193.
18. Naramura M, Gillies SD, Mendelsohn J, Reisfeld RA, Mueller BM., Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma. Cancer Immunol Immunother 1993; 37: 343.
19. Cappuzzo F, Hirsch FR, Rossi E, et al., Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005; 97: 643.
20. Tsao MS, Sakurada A, Cutz JC, et al., Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005; 353: 133.
21. Liu W, Innocenti F, Wu MH, et al., A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter. Cancer Res 2005; 65: 46.
22. Montero AJ, Diaz-Montero CM, Mao L, et al., Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 2006; 5: 1494.
23. Shtiegman K, Kochupurakkal BS, Zwang Y, et al., Defective ubiquitinylation of EGFR mutants of lung cancer confers prolonged signaling. Oncogene 2007; 26: 6968.
24. Grandal MV, Zandi R, Pedersen MW, Willumsen BM, van Deurs B, Poulsen HS., EGFRvIII escapes down-regulation due to impaired internalization and sorting to lysosomes. Carcinogenesis 2007; 28: 1408.
25. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M., Expression of cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J Cancer 1994; 56: 853.
26. Gordon-Thomson C, Jones J, Mason RS, Moore GP., ErbB receptors mediate both migratory and proliferative activities in human melanocytes and melanoma cells. Melanoma Res 2005; 15: 21.
27. Ueno Y, Sakurai H, Tsunoda S, et al., Heregulin-induced activation of ErbB3 by EGFR tyrosine kinase activity promotes tumor growth and metastasis in melanoma cells. Int J Cancer 2008; 123: 340.
28. Reschke M, Mihic-Probst D, van der Horst EH, et al., HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 2008; 14: 5188.
29. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, et al., Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67: 2643.
30. Frattini M, Saletti P, Romagnani E, et al., PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139.
31. Whitwam T, Vanbrocklin MW, Russo ME, et al., Differential oncogenic potential of activated RAS isoforms in melanocytes. Oncogene 2007; 26: 4563.
32. Davies H, Bignell GR, Cox C, et al., Mutations of the BRAF gene in human cancer. Nature 2002; 417: 949.
33. de Snoo FA, Hayward NK., Cutaneous melanoma susceptibility and progression genes. Cancer Lett 2005; 230: 153.